Prevalence and Impact of Pulmonary Hypertension on Acute Decompensated Heart Failure with Preserved Ejection Fraction Hospitalizations: A Five-Year Retrospective Analysis.
Heart Failure
Outcomes
Preserved Ejection Fraction
Pulmonary Hypertension
Journal
Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
received:
18
03
2024
accepted:
20
03
2024
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
24
3
2024
Statut:
aheadofprint
Résumé
Heart Failure with Preserved Ejection Fraction (HFpEF) is a major and common cardiovascular condition with widely variable clinical outcomes. Pulmonary hypertension (PH) often co-exists with HFpEF and tends to affect patient outcomes; this study aims to identify the impact of PH on the clinical outcome of patients admitted to the hospital with acute HFpEF exacerbations. We analyzed data from the National Inpatient Sample between 2016 and 2020, focusing on 464,438 acute HFpEF exacerbation hospitalizations. Outcomes were compared between those with PH (27.1%) and those without PH (72.9%). HFpEF hospitalizations with PH exhibited elevated in-hospital mortality (adjusted odds ratio [aOR]: 1.20, 95% confidence interval [95 CI]: 1.08-1.31, P <0.05), prolonged length of stay (adjusted β: 0.90 days, P <0.05), and increased overall costs (adjusted β: $2,858, P <0.05). Furthermore, HFpEF hospitalizations with PH demonstrated higher rates of atrial fibrillation, ventricular tachycardia, right ventricular failure, and conduction abnormalities. This population also displayed an increased incidence of acute hypoxic respiratory failure, necessitating increased non-invasive and mechanical ventilation. The co-existence of PH in HFpEF presents an increased risk of mortality and morbidity, with higher healthcare costs and the need for ventilatory support, in addition to higher risks of cardiovascular and pulmonary complications. Therefore, an early diagnosis of PH in patients with HFpEF is crucial, and further research is required to determine appropriate management.
Identifiants
pubmed: 38522770
pii: S0146-2806(24)00176-2
doi: 10.1016/j.cpcardiol.2024.102537
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102537Informations de copyright
Copyright © 2024. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors have participated in the work and have reviewed and agree with the content of the article.